ArticleFrontiers in endocrinology2026
Estradiol negatively associates with metabolic dysfunction-associated steatotic liver disease in children.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease in children and adolescents. Studies in adults indicate that MASLD is more prevalent in males compared to females and that sex hormones may play a significant role in MASLD development. However, limited pediatric research is available on the relation between sex hormones and MASLD. This study investigates associations between sex hormones and MASLD in children with overweight and obesity. Methods: A cross-sectional study was conducted in children with overweight and obesity in a tertiary care center (Maastricht UMC+). A comprehensive serum sex hormone panel, serum alanine aminotransferase (ALT) and hepatic steatosis on ultrasound (HS) were determined in 290 participants. Controlled Attenuation Parameter (CAP, measured with FibroScan) was available in 75 participants. Associations between sex hormones and MASLD parameters (ALT, HS and CAP) were investigated. Results: This study found that estradiol, Anti-Müllerian hormone (AMH) and sex hormone-binding globulin (SHBG) inversely associated with ALT (p=0.018, p=0.048 and p<0.001). Free (FT) and bioavailable (BT) testosterone and dehydroepiandrosterone sulfate (DHEAS) positively associated with ALT (both p=0.006). In addition to this, AMH and SHBG inversely associated with HS (p=0.028 and p<0.001), while FT, BioT and DHEAS positively associated with HS (p=0.024, p=0.024 and p=0.042). Lastly, AMH and SHBG inversely associated with CAP (p=0.04 and p<0.001), whereas follicle stimulating hormone, total testosterone (TT), FT, BioT, androstenedione and DHEAS positively associated (p=0.034, p=0.04, p=0.032, p=0.032, p=0.007 and p=0.003). Conclusions: Estradiol, AMH and SHGB inversely associate with MASLD parameters, while androgens, including TT, FT, BioT, and DHEAS, positively associate with MASLD parameters in children with overweight and obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.